ALERT: This system is being upgraded on Tuesday December 12. It will not be available
for use for several hours that day while the upgrade is in progress. Deposits to DukeSpace
will be disabled on Monday December 11, so no new items are to be added to the repository
while the upgrade is in progress. Everything should be back to normal by the end of
day, December 12.
Browsing by Author "Frye, Mark A"
Now showing items 1-5 of 5
-
Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression.
(Translational psychiatry, 2021-03-02)Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for major depressive disorder (MDD), yet their mechanisms of action are not fully understood and their therapeutic benefit varies among individuals. ... -
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.
(Translational psychiatry, 2019-07-04)Metabolomics provides valuable tools for the study of drug effects, unraveling the mechanism of action and variation in response due to treatment. In this study we used electrochemistry-based targeted metabolomics to gain ... -
Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.
(Clinical pharmacology and therapeutics, 2019-10)We set out to determine whether machine learning-based algorithms that included functionally validated pharmacogenomic biomarkers joined with clinical measures could predict selective serotonin reuptake inhibitor (SSRI) ... -
Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment.
(Frontiers in neuroscience, 2019-01)Major depressive disorder (MDD) is a common and disabling syndrome with multiple etiologies that is defined by clinically elicited signs and symptoms. In hopes of developing a list of candidate biological measures that reflect ... -
Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings.
(Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2021-06)Heterogeneity in the clinical presentation of major depressive disorder and response to antidepressants limits clinicians' ability to accurately predict a specific patient's eventual response to therapy. Validated depressive ...
